Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIVPRNewsWire • 09/05/23
CVS Health Just Created a New Problem For Viatris. Here's What You Need to KnowThe Motley Fool • 09/01/23
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 08/30/23
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 08/23/23
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]PRNewsWire • 08/07/23
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple SclerosisPRNewsWire • 08/07/23
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 YearsThe Motley Fool • 08/04/23